Søren Westh Lonning has been appointed the new Chief Financial Officer (CFO) and member of the Executive Board of Chr. Hansen Holding A/S.
Søren Westh Lonning (38) is currently Managing Director with responsibility for South West Europe and Vice President Finance for the EMEA region at Chr. Hansen.
In the period 2007-2013, Søren held positions as Vice President for Business Finance and Sourcing, Finance Director for the Cultures & Enzymes and Health & Nutrition Divisions, and Director of Corporate Development at Chr. Hansen. Before joining Chr. Hansen, he was Investment Manager at Axcel Private Equity and, prior to that, an Associate at McKinsey & Co.
Søren holds an M.Sc. in Finance and Accounting (cand.merc.fir.) from Copenhagen Business School.
“I am extremely excited about assuming the position of CFO of Chr. Hansen after close to eight years with the company. Chr. Hansen is a truly fantastic company with many attractive growth opportunities and great employees, and I look forward to continuing being part of the future development of the company as a member of Chr. Hansen’s Executive Board,” says Søren Westh Lonning.
Søren will take up his new position on 1 August 2015. From this date, the Chr. Hansen Executive Board will consist of CEO Cees de Jong, EVP Knud Vindfeldt and CFO Søren Westh Lonning.
“Søren has a strong financial background from national as well as international positions, a great knowledge of Chr. Hansen and its products, and broad leadership experience, all competencies that are well suited to the job as CFO, and I am therefore very happy that we are able to appoint a highly qualified internal successor,” says Cees de Jong, CEO.
For further information, please contact:
Anders Mohr Christensen, Senior Director, Investor Relations
Tel: +45 4574 7618
Helle Rexen, Corporate Communications
Tel: +45 4574 7636
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.